Drug Repurposing Against SARS-CoV-1, SARS-CoV-2 and MERS-CoV

Aherfi, Sarah; Pradines, Bruno; Devaux, Christian; Honoré, Stéphane; Colson, Philippe; Scola, Bernard La; Raoult, Didier

doi:10.2217/fmb-2021-0019

Cited by 30 publications

(31 citation statements)

References 205 publications

(262 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By preventing virus entry and/or its replication or clearing of cells into which the virus has already entered, effective treatments with antivirals can help to slow the spread of a person's infection, potentially reducing the length and severity of symptoms. Thus, safe and effective antivirals responsible for restricting viral entry and/or disruption of the replication process are crucial to the pandemic response [5][6][7][8][9][10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

RETRACTED: Artemisia Extracts and Artemisinin-Based Antimalarials for COVID-19 Management: Could These Be Effective Antivirals for COVID-19 Treatment?

Agrawal¹,

Agrawal²,

Blunden

2022

Molecules

View full text Add to dashboard Cite

As the world desperately searches for ways to treat the coronavirus disease 2019 (COVID-19) pandemic, a growing number of people are turning to herbal remedies. The Artemisia species, such as A. annua and A. afra, in particular, exhibit positive effects against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and COVID-19 related symptoms. A. annua is a source of artemisinin, which is active against malaria, and also exhibits potential for other diseases. This has increased interest in artemisinin’s potential for drug repurposing. Artemisinin-based combination therapies, so-called ACTs, have already been recognized as first-line treatments against malaria. Artemisia extract, as well as ACTs, have demonstrated inhibition of SARS-CoV-2. Artemisinin and its derivatives have also shown anti-inflammatory effects, including inhibition of interleukin-6 (IL-6) that plays a key role in the development of severe COVID-19. There is now sufficient evidence in the literature to suggest the effectiveness of Artemisia, its constituents and/or artemisinin derivatives, to fight against the SARS-CoV-2 infection by inhibiting its invasion, and replication, as well as reducing oxidative stress and inflammation, and mitigating lung damage.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED: Artemisia Extracts and Artemisinin-Based Antimalarials for COVID-19 Management: Could These Be Effective Antivirals for COVID-19 Treatment?

Agrawal¹,

Agrawal²,

Blunden

2022

Molecules

View full text Add to dashboard Cite

show abstract

“…Drug repurposing refers to the discovery of new therapeutic uses of clinically available drugs. It is a prompt strategy in searching of medications for COVID-19 therapy since the traditional drug discovery process can be costly and takes decades to complete ( Aherfi et al, 2021 ; Hijikata et al, 2021 ; Mslati et al, 2021 ; Shende et al, 2021 ). As repurposed drugs have gone through clinical trial, important parameters of these drugs, such as inhibitory potential, cell permeability, bio-availability, and safety, have been well characterized and can be available in a short time in face of pandemics ( Pushpakom et al, 2019 ).…”

Section: Strategies In Plpro Inhibitor Developmentmentioning

confidence: 99%

Potential Inhibitors Targeting Papain-Like Protease of SARS-CoV-2: Two Birds With One Stone

2022

View full text Add to dashboard Cite

Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), the pathogen of the Coronavirus disease-19 (COVID-19), is still devastating the world causing significant chaos to the international community and posing a significant threat to global health. Since the first outbreak in late 2019, several lines of intervention have been developed to prevent the spread of this virus. Nowadays, some vaccines have been approved and extensively administered. However, the fact that SARS-CoV-2 rapidly mutates makes the efficacy and safety of this approach constantly under debate. Therefore, antivirals are still needed to combat the infection of SARS-CoV-2. Papain-like protease (PLpro) of SARS-CoV-2 supports viral reproduction and suppresses the innate immune response of the host, which makes PLpro an attractive pharmaceutical target. Inhibition of PLpro could not only prevent viral replication but also restore the antiviral immunity of the host, resulting in the speedy recovery of the patient. In this review, we describe structural and functional features on PLpro of SARS-CoV-2 and the latest development in searching for PLpro inhibitors. Currently available inhibitors targeting PLpro as well as their structural basis are also summarized.

show abstract

“…Pyronaridine alone also demonstrated significant activity in the guinea pig-adapted model of EBOV infection. 17 We and others 18 − 21 have recently shown that these compounds possess in vitro activity against SARS-CoV-2, and tilorone and pyronaridine are in clinical trials, the latter in combination with artesunate. The C max data for pyronaridine in our previous mouse pharmacokinetics studies (i.p.…”

mentioning

confidence: 99%

Pyronaridine Protects against SARS-CoV-2 Infection in Mouse

et al. 2022

View full text Add to dashboard Cite

There are currently relatively few small-molecule antiviral drugs that are either approved or emergency-approved for use against severe acute respiratory coronavirus 2 (SARS-CoV-2). One of these is remdesivir, which was originally repurposed from its use against Ebola. We evaluated three molecules we had previously identified computationally with antiviral activity against Ebola and Marburg and identified pyronaridine, which inhibited the SARS-CoV-2 replication in A549-ACE2 cells. The in vivo efficacy of pyronaridine has now been assessed in a K18-hACE transgenic mouse model of COVID-19. Pyronaridine treatment demonstrated a statistically significant reduction of viral load in the lungs of SARS-CoV-2-infected mice, reducing lung pathology, which was also associated with significant reduction in the levels of pro-inflammatory cytokines/chemokine and cell infiltration. Pyronaridine inhibited the viral PL pro activity in vitro (IC 50 of 1.8 μM) without any effect on M pro , indicating a possible molecular mechanism involved in its ability to inhibit SARS-CoV-2 replication. We have also generated several pyronaridine analogs to assist in understanding the structure activity relationship for PL pro inhibition. Our results indicate that pyronaridine is a potential therapeutic candidate for COVID-19.

show abstract

Drug Repurposing Against SARS-CoV-1, SARS-CoV-2 and MERS-CoV

Cited by 30 publications

References 205 publications

RETRACTED: Artemisia Extracts and Artemisinin-Based Antimalarials for COVID-19 Management: Could These Be Effective Antivirals for COVID-19 Treatment?

RETRACTED: Artemisia Extracts and Artemisinin-Based Antimalarials for COVID-19 Management: Could These Be Effective Antivirals for COVID-19 Treatment?

Potential Inhibitors Targeting Papain-Like Protease of SARS-CoV-2: Two Birds With One Stone

Pyronaridine Protects against SARS-CoV-2 Infection in Mouse

Contact Info

Product

Resources

About